Childhood B Acute Lymphoblastic Leukemia - calaspargase pegol-mknl - No biomarker

Association details:

Biomarker:	No biomarker
Cancer:	Childhood B Acute Lymphoblastic Leukemia
Drug:	Asparlas (calaspargase pegol-mknl) (Asparagine depleter, Aspartate-ammonia ligase inhibitor)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: A1 - Approval

Source:

FDA

Published date:

11/29/2023

Excerpt:

ASPARLAS is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.